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NON-CLASSIC ADRENAL HYPERPLASIA AND 
TYPE 2 DIABETES 
Beginning with our observations in the 1990s that 
many patients with Type 2 diabetes (T2DM) have 
clinical signs and symptoms of hyperandrogenism such 
as hirsutism, male pattern alopecia, acne, menstrual 
irregularity, and infertility we went on to systematically 
evaluate these patients for hyperandrogenism and 
found that, with the notable exception of patients 
whose Type 2 diabetes developed in the setting of 
chronic Hepatitis C and no known family history of 
Type 2 diabetes, all had evidence of non-classic 
adrenal hyperplasia (NCAH) [1-4]. Subsequently, we 
found this relationship to be true even in those T2DM 
patients without clinical features of hyperandrogenism. 
NON-CLASSIC ADRENAL HYPERPLASIA AND 
AUTOIMMUNE DISORDERS 
Having demonstrated that T2DM is consistently 
associated with NCAH we began to wonder if Type 1 
diabetes (T1DM) was also associated with NCAH. 
Once again, we found that all of our T1DM patients had 
evidence of NCAH [5]. We now began to speculate 
whether NCAH might be a feature of autoimmune 
disorders in general. It should be remembered that at 
this time, T2DM was not considered to have 
autoimmunity as part of its pathogenesis (see Dr. 
Banerji's lecture), although its association with certain 
autoimmune disorders, eg psoriasis and vitiligo, was 
widely recognized. Currently, it is recognized that 
autoimmunity contributes to the pathogenesis of T2DM 
[6]. 
We systematically screened our patients with a 
number of autoimmune disorders including: 
Hashimoto's thyroiditis, Graves' Disease, vitiligo,  
 
 
*Address correspondence to this author at the Chief, Endocrine Division, NYC 
Health+Hospitals/Woodhull Clinical Professor of Medicine, SUNY Downstate 
Medical Center& NYU School of Medicine Professor of Medicine, St. George’s 
University, Brooklyn, New York, USA; Tel: +13476458255;  
E-mail: Alan.Sacerdote@woodhullhc.nychhc.org 
psoriasis, and rheumatoid arthritis [7-11] for NCAH and 
found that NCAH was virtually universally present in 
these patients. Although we have seen only very small 
numbers of patients with other autoimmune disorders, 
the few that we have seen with systemic lupus 
erythematosus, celiac disease, and inflammatory bowel 
disease all seem to have NCAH. 
POSSIBLE REASONS FOR THE HIGH 
PREVALENCE OF NCAH IN PATIENTS WITH 
AUTOIMMUNE DISORDERS 
Our reported findings raise the question of why 
NCAH should be so prevalent in patients with 
autoimmunity. Several possible explanations are 
possible.  
First, let us consider that the hormone cortisol and 
its glucocorticoid analogues, eg prednisone, are 
standard therapies for many autoimmune disorders. In 
NCAH there is always a mild, chronic deficit of cortisol. 
Could a mild, yet persistent, deficit of an anti-
autoimmune hormone eventually result in the 
expression of an autoimmune disorder in those who 
are genetically or epigenetically pre-disposed to such 
disorders? 
Next, let us consider the location of the 21-
hydroxylase gene, the gene most commonly 
associated with both NCAH and classic congenital 
hyperplasia (CAH). It is located in chromosome 6 within 
the major histocompatibility (MHC) locus and 
contiguous with the tenascin X gene. Tenascin X is a 
collagen protein and, as such, is a component of 
connective tissue. Both the hyperelasticity (Ehlers-
Danlos) syndrome and cardiac valvulopathies have 
been reported in patients with contiguous mutations in 
the 21-hydroxylase and tenascin XB genes [12]. It is 
not hard to conceive that a mutant tenascin XB protein 
might be more difficult for the immune system to 
recognize as a self-protein to be tolerated, thus 
facilitating a humoral and cellular immune response 
against connective tissue containing the abnormal 
12     Journal of Autoimmune Diseases and Rheumatology, 2018, Vol. 6 Alan Sacerdote 
collagen. Similarly, an abnormal, mutant 21-
hydroxylase protein might not be recognized as self 
and facilitate the development of autoimmune adrenal 
insufficiency (Addison's disease). This would also be 
true for mutant forms of other adrenal steroidogenic 
proteins such as 11-hydroxylase. 
In addition to proximity to the tenascin XB gene, the 
21-hydroxylase gene is also in close proximity to 
numerous genes within the MHC locus, polymorphisms 
of which are highly associated with autoimmune 
disorders, including Autoimmune Polyglandular 
Syndrome 2. This close proximity allows for frequent 
simultaneous polymorphisms in both MHC genes and 
the 21-hydroxylase gene. 
The gene for the 4th component of complement 
(C4) is also located very close to the 21-hydroxylase 
locus. Complement is an integral part of the innate 
immune system. Genetic deficiency of any early 
component of the classical pathway (C1q, C1r/s, C2, 
C4, and C3) is associated with autoimmune diseases 
due to the failure of clearance of immune complexes 
(IC) and apoptotic materials, and the impairment of 
normal humoral response. Thus, mutations of both the 
21-hydroxylase and C4 genes could easily occur 
simultaneously, resulting in both NCAH and an 
autoimmune disorder [12-13]. 
Insulin Resistance in NCAH 
As insulin sensitizers became available, first 
metformin and then the thiazolidinediones, we began to 
notice that many of our patients with T2DM and NCAH 
were experiencing improvements in their alopecia, 
hirsutism, acne, menstrual irregularity, and infertility 
after starting these agents. We began to wonder 
whether IR was necessary for NCAH to be expressed. 
When we retested our diabetic and prediabetic patients 
with NCAH while taking metformin +\- troglitazone we 
found that in every instance the initially elevated steroid 
metabolite eg 17-OH-progesterone, had declined- in 
most cases, back into the normal range [2,3, 14-15]. 
Sparse reports began to appear in the literature [16-
17] from Dr. New's group at New York Hospital and Dr. 
Saygili's group in Turkey that IR was a regular feature 
of patients with NCAH. However, neither group 
suggested targeting the IR as a means of treating the 
NCAH. 
Insulin Resistance in Classic CAH 
As adult endocrinologists, we saw few patients with 
classic CAH, as they tend to remain under the care of 
their pediatric endocrinologists until well into adulthood. 
Nevertheless, we wondered whether IR was also a 
characteristic of patients with classic CAH as well. An 
article by Charmandari et al. from Dr. Chrousos' group 
at the National Institutes of Health [18] and a case 
report from Turkey [19] went a long way toward 
answering this crucial question. They reported that 102 
patients with classic CAH, 100 with 21-hydroxylase 
deficiency and 2 patients with 11-hydroxylase 
deficiency all had IR, independently of their 
glucocorticoid therapy. Again, while the authors 
recognized this as a problem which could increase their 
patients' risk of developing complications of IR such as 
metabolic syndrome and T2DM, they did not raise the 
possibility that addressing the IR might ameliorate the 
classic CAH. This possibility would wait until our 
colleague, Dr. Levon Agdere, a pediatric 
endocrinologist, called us to say that he was seeing a 
17 year old female patient with classic 21-hydroxylase 
deficiency, who, despite receiving optimal traditional 
treatment with cortisone acetate and fludrocortisone, 
had recently developed amenorrhea and hirsutism. The 
serum 17-OH-progesterone was still very high around 
3500 ng/dl and the serum testosterone was still in the 
adult male range (>300) (see Figures 1,2).  
 
Figure 1: Change in Serum 17-OH-progesterone (ng/dl) after 
metformin 500 mg twice daily (met500bid) was added to 
standard steroid treatment in a patient with classic 21-
hydroxylase deficiency. 
Most authorities caution against attempting to 
normalize the levels of 17-OH-progesterone and 
androgens in these patients due to glucocorticoid side 
effect such as hypertension, hyperglycemia, bone loss, 
hypokalemia, affective changes, and weight gain when 
supra-physiologic doses are used.  
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Figure 2: Change in Serum total testosterone (ng/dl) after 
metformin 500 mg twice daily (met500bid) was added to 
standard steroid treatment in a patient with classic 21-
hydroxylase deficiency. 
TARGETING INSULIN RESISTANCE IN CLASSIC 
CAH 
We agreed, after obtaining informed consent from 
the patient and her parents, to continue her on her 
regimen of cortisone acetate + fludrocortisone and to 
add the insulin sensitizing, anti-diabetic agent, 
metformin, starting at 500 mg twice daily. When she 
returned to Dr. Adgere's clinic 3 months later she had 
resumed monthly menses and stated that she had to 
remove to remove unwanted hair less often. Her repeat 
serum 17-OH-progesterone and total testosterone 
levels had both declined by about 50% [20]. She was 
offered the opportunity to uptitrate the dosage of 
metformin and possibly add a second insulin sensitizer 
in an attempt to normalize her serum 17-OH-
progesterone and testosterone concentrations and 
gradually wean her off steroids. The patient, however, 
thanked Dr. Agdere for the improvement she had 
experienced up to this point and declined any further 
change in her therapy. Thus, to date, we are to unable 
to say definitively whether or not insulin sensitizers can 
eliminate the need for steroids in classic 21-
hydroxylase deficiency as they do in NCAH.  
On the other hand, we have been able to 
demonstrate that in a patient with both classic CAH due 
to 11-hydroxylase deficiency and Vitamin D deficiency 
repletion of Vitamin D, using ergocalciferol 50,000 IU 
weekly, his serum 11-deoxycortisol was normalized 
without using steroids [21] (Figure 3). 
TARGETING INSULIN RESISTANCE IN NCAH 
Another patient we were consulted on to help 
improve his glycemic control as his surgical team 
attended to his serious lower extremity infection. 
Endocrine investigation revealed that the patient, a 
middle-aged physician from Jamaica, had both non-
classic 21-hydroxylase deficiency and Vitamin D 
insufficiency. Given his serious infection we could not 
use metformin to treat either his diabetes or his NCAH 
because of the risk of precipitating lactic acidosis. 
Ergocalciferol 50,000 IU every 2 weeks was begun. 
Within 2 weeks his serum 25-OH-Vitamin D had nearly 
normalized and his serum 17-OH-progesterone had 
normalized [22] (Figure 4). 
Weight loss is another way that IR may be reduced. 
Is weight loss a viable way to treat NCAH as it in 
polycystic ovarian syndrome (PCOS)? This question 
was partially answered by 2 of our patients who both 
had hirsutism, Class 1 obesity, and non-classic 
aldosterone synthase deficiency. This form of NCAH 
was first reported by E Philip Osehobo and myself in 
1998 [23]. I told the first of these 2 patients that the 
most logical means of treating her aldosterone 
synthase deficiency was with the synthetic 
mineralocorticoid, fludrocortisone. She said that she felt 
that if she adopted a healthier lifestyle her condition 
would improve. She asked me for a referral to a 
nutritionist and joined a gym, which she did and 
attended regularly. When she returned 3 months later 
she had lost 10% of both her body weight and her BMI. 
She reported that she had to remove facial and body 
hair less frequently. Her previously elevated serum 
deoxycorticosterone fell by 50%, into well within the 
normal range, and her previously elevated LH/FSH 
ratio also normalized [24]. Following this favorable 
outcome, the same therapeutic approach was used in 
another patient with non-classic aldosterone synthase 
 
Figure 3: Response of serum 11-deoxycortisol (ng/dl) to 
Vitamin D repletion in a patient with classic 11-hydroxylase 
deficiency. 
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deficiency with comparable results. Pooled data for 
these 2 patients is shown in Figure 5. 
 
Figure 5: Response of 2 patients’ weight, body mass index 
(BMI), serum deoxycorticosterone (DOC) (ng/dl), & luteinizing 
hormone/follicle stimulating hormone (LH/FSH) to lifestyle 
changes. 
Percent Changes with Weight Loss. 
After troglitazone was withdrawn from the market 
due to its rare, idiosyncratic, but very serious liver 
toxicity, two other thiazolidinediones that did not have 
this issue, were released, rosiglitazone and 
pioglitazone. NCAH patients that we treated with these 
agents responded similarly to those that we had treated 
earlier with troglitazone, again paralleling the 
experience that was being reported using these agents 
in PCOS patients. 
DRUGS THAT CAUSE IR CAUSE EXPRESSION OF 
NCAH, A FORM OF ENDOCRINE DISRUPTION 
If IR is a constant feature of both NCAH and classic 
CAH it is logical to ask whether medications known to 
cause IR can induce the expression of NCAH and 
whether interventions that reduce IR can ameliorate 
such NCAH. One such group of drugs is the classic 
and atypical anti-psychotic drugs. Another frequently 
prescribed psychotropic agent is valproic acid. We 
screened 27 consecutive psychiatric in-patients who 
were taking one or more of these agents who we had 
been called to see for endocrine consultations. 27/27 of 
these patients had biochemical NCAH, many with 
clinical features such as hirsutism, acne, alopecia, and 
irregular menses.  
Two other classes of drugs which also cause IR are 
the protease inhibitors and the nucleoside analogues, 
both used anti-retroviral therapy. We screened 11 
HIV+ve patients who were taking drugs from one or 
both of these classes and found that 11/11 had NCAH 
[25]. We did not, however, have the opportunity to treat 
this group of patients with insulin sensitizers. 
INSULIN SENSITIZERS REVERSE DRUG-INDUCED 
NCAH EXPRESSION 
When treated with insulin sensitizers-metformin 
alone or with rosiglitazone or rosiglitazone alone 27/27 
patients experienced biochemical normalization [15].  
EFFECT OF BARIATRIC SURGERY IN NCAH 
While lifestyle changes can result in a reduction in 
IR and amelioration of both NCAH and PCOS, it is 
known that bariatric surgery can result in even more 
rapid and dramatic improvements in insulin sensitivity. 
When one of our patients with morbid obesity, T2DM, 
hypertension, dyslipidemia, and hirsutism associated 
with non-classic 11-hydroxylase deficiency opted to 
undergo Roux-en-Y gastric bypass surgery we fully 
expected amelioration of her first four issues. Based on 
 
Figure 4: Response of serum 17-OH-progesterone (ng/dl) to vitamin D repletion in a patient with non-classic 21-hydroxylase 
deficiency. 
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our previous experience with this patient using a 
combination of the insulin sensitizers, metformin and 
pioglitazone, which normalized her serum 11-
deoxycortisol we predicted the same would occur 
following bariatric surgery. When we saw her 5 weeks 
after her surgery she had lost 7 kg, she was 
euglycemic, normolipidemic, and normotensive without 
medication and her serum 11-deoxycortisol remained 
normal [26] (Figure 6). 
 
Figure 6: Changes in serum 11-deoxycortisol (ng/dl) with 
metformin+pioglitazone (met+pio) and 5 weeks Post-Roux-
en-Y gastric bypass (post-op) off medication. 
Two other patients afforded us the opportunity to 
explore a complementary treatment for NCAH. The first 
patient, a 57 year old woman, complained of excessive 
scalp hair loss, despite appearing to have a luxuriant 
head of hair. She then showed me a photograph on her 
smart phone of how her pillow looked when she got up 
on a recent morning-it was covered with hair. 
Investigation revealed that she had both non-classic 3-
beta-hydroxysteroid dehydrogenase deficiency and 
aldosterone synthase deficiency. Initially she was 
treated with pioglitazone 15 mg daily. At her 
subsequent visit 3 months later her daily hair loss was 
much less, which she documented with another smart 
phone photo. In addition, her previously very elevated 
levels of 17-OH-pregnenolone and corticosterone had 
normalized. Despite being very pleased with the results 
she had achieved, she elected not to continue taking 
pioglitazone because of potential risks of osteoporosis, 
bladder cancer, and weight gain. I offered her a 
prescription for the insulin sensitizer metformin, noting 
that its use was not associated with any of these side 
effects, as an alternative. When she returned 3 months 
later, she was still very pleased that her rate of hair 
loss had not increased and I was also pleased to note 
that her serum concentrations of both 17-OH-
pregnenolone and corticosterone remained normal. I 
immediately attributed this therapeutic success to 
metformin. She looked at me rather sheepishly and 
then told me that she filled the metformin prescription 
at her pharmacy, but had never actually started to take 
it. Two days after her previous visit with me she had 
been watching Dr. Oz, a popular, nationally syndicated 
television program about health issues.  
During this program Dr. Oz discussed some of the 
attributes of the Aryuvedic herb, Ashwagandha 
(Withania somnifera) including it being a general tonic 
and an adaptogen (Adaptogens or adaptogenic 
substances are used in herbal medicine for the claimed 
stabilization of physiological processes and promotion 
of homeostasis). He did not claim any specific benefit 
insofar as hair loss was concerned. 
She then purchased this product from the 
recommended manufacturer and started to take it at 
the dose recommended by Dr. Oz, 400 mg twice daily 
[27] (Figure 7).  
 
Figure 7: Response of a patient with both non-classic 
aldosterone synthase deficiency and non-classic 3-β-ol-
dehydrogenase deficiency to Ashwagandha root 400 mg 
2x/day. 
After this patient's gratifying response to 
Ashwagandha we recommended it to a second patient, 
an 80 year old woman who was complaining of thinning 
scalp hair and acne, in whom recent investigation 
revealed non-classic 11-hydroxylase deficiency to be 
the likely cause of her complaints. Metformin was not 
an option because this patient had chronic kidney 
disease stage 3b. The patient had indicated her strong 
preference for "natural" treatment of her NCAH. We 
initiated treatment with the same dose of Ashwagandha 
we had used successfully with the previous patient, 
400 mg twice/day. While her acne and hair loss 
noticeably improved on this dose and her serum 11-
deoxycortisol improved considerably, her serum 11-
deoxycortisol did not normalize until a dose of 800 mg 
twice/day was reached [28] (Figure 8). 
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After having demonstrated that Vitamin D repletion 
in Vitamin D deficient/insufficient people often 
ameliorates NCAH/ CAH a patient with hypovitaminosis 
D (baseline 25-OH-vitamin D3=24.4 ng/ml) and non-
classic 11-hydroxylase deficiency (baseline serum 11-
deoxycortisol=62 ng/dl) was seen in consultation. He 
had recently undergone a partial bowel resection and 
was being fed by total parenteral nutrition (TPN). TPN, 
being aqueous, does not contain Vitamin D, which is 
lipid soluble. Hypovitaminosis D was exacerbated by 
lack of access to any natural or artificial ultraviolet light 
source. When next sampled, about 2 weeks later he 
had severe Vitamin D deficiency (10.3 ng/ml) and his 
serum 11-deoxycortisol had risen impressively to 246 
ng/dl ng/dl. As oral or enteral feeding still had not been 
initiated, his severe Vitamin D deficiency persisted 
(12.7 ng/ml) and his serum 11-deoxycortisol rose 
astronomically (1486 ng/dl) [29] (Figure 9). It had now 
been demonstrated not only that hypovitaminosis D 
was frequently encountered in patients with NCAH and 
CAH and that Vitamin D repletion generally ameliorated 
both conditions, but that the converse was also true-
that worsening and prolonged Vitamin D deficiency is 
associated with exacerbation of NCAH. 
One of our patients with a diagnosis of non-classic 
11-hydroxylase deficiency and prediabetes with a chief 
complaint of thinning scalp hair was prescribed 
 
Figure 8: Dose-related response of serum 11-deoxycortisol to Ashwagandha root in a patient with non-classic 11-hydroxylase 
deficiency. 
 
 
Figure 9: Increase in serum 11-deoxycortisol with worsening and prolonged hypovitaminosis D in a patient with non-classic 11-
hydroxylase deficiency. 
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metformin to address these issues. She only took 
metformin for 2 days after which she purchased an 
over the counter preparation called Hair, Skin, and 
Nails containing beta carotene 2500 IU, Vitamin C 100 
mg, biotin 2500 mcg, zinc oxide 11 mg, and copper 
oxide 0.9 mg for 114 days. When she returned both her 
serum 11-deoxycortisol and her hemoglobin A1c had 
normalized (Figures 10-11). 
An interesting study from Poland suggests that it 
may be hyperinsulinemia, which typically is a 
compensatory accompaniment to IR, rather than IR 
itself, that may be the critical factor in the expression of 
NCAH [30]. In this study 4 women with both 
hypercholesterolemia and non-classic 21-hydroxylase 
deficiency, who were already taking metformin, were 
treated with simvastatin for their hypercholesterolemia. 
Statin drugs are known to reduce serum insulin levels, 
which is believed to be one the mechanisms for their 
mildly diabetogenic effect. All 4 patients not only 
reduced their serum total and LDL cholesterol and their 
serum insulin concentrations but they normalized their 
elevated serum 17-OH-progesterone concentrations as 
well. 
INSULIN SENSITIZERS AND AUTOIMMUNITY 
There is a growing body of literature reporting that 
interventions known to decrease IR, including 
metformin [31-35], pioglitazone [32, 36,37,38], weight 
loss [39], bariatric surgery [40], Ashwagandha [41], and 
Vitamin D repletion have efficacy in prevention of some 
and amelioration of a number of autoimmune disorders 
[42-50]. Curcumins derived from turmeric have both 
insulin-sensitizing and anti-autoimmune effects [51]. 
THE GUT BIOME 
There are also broad similarities in the gut biome of 
people with IR/metabolic syndrome and those with 
many autoimmune disorders, characterized by a 
 
Figure 10: Normalization of serum 11-deoxycortisol with “Hair, Skin, & Nails” (H,S,& K) in a patient with non-classic 11-
hydroxylase deficiency and prediabetes. 
 
 
Figure 11: Change in HbA1C with “Hair, Skin, & Nails” (H,S, & K) in a patient with non-classic 1-hydroxylase deficiency and pre-
diabetes. 
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decrease in both total number and species diversity of 
organisms. Improvements in insulin sensitivity are 
associated with increases in species diversity and 
absolute number of organisms [52]. Conversely, fecal 
transplants from insulin sensitive individuals to insulin-
resistant individuals will restore insulin sensitivity to the 
latter, however, their biome will revert to IR type unless 
their lifestyle changes as well, to one characterized by 
a more plant-based diet and more physical activity [54-
55]. 
What we are seeing are myriad interconnections 
between insulin resistance/hyperinsulinemia, 
congenital adrenal hyperplasia, Vitamin D, and the gut 
biome. These interconnections offer us many potential 
therapeutic targets to benefit our patients. Single 
interventions often have a multiplicity of benefits. 
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